Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Struggling 2Seventy scraps a key cancer study
2Seventy bio halts enrollment in a key multiple myeloma study for its therapy Abecma to save $80 million, aiming for financial break-even next year. Despite this, Abecma shows growth, with U.S. revenue expected to rise 30% in Q3. The decision reflects an improved treatment landscape for newly diagnosed patients, reducing eligible participants.
Related Clinical Trials:
Avantor® Joins Pharmaceutical Industry-Sponsored Energize Virtual Power Purchase Agreement
Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.
Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of ...
Novavax appoints Ruxandra Draghia-Akli, MD, PhD, as EVP and Head of R&D in November 2024, leveraging her 20+ years of clinical, corporate, and global public health expertise to evaluate the company's pipeline and Matrix-M™ adjuvant technology.
Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain ...
Generics and biosimilars saved $445 billion in 2023, but challenges like high out-of-pocket costs, drug shortages, and ineffective policies limit their impact. AAM's report highlights the need for policy changes to ensure patient access and market sustainability.
Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living ...
Johnson & Johnson submitted a Biologics License Application to the FDA for nipocalimab, seeking approval for treating generalized myasthenia gravis (gMG). The Phase 3 Vivacity-MG3 study showed superior outcomes for antibody-positive participants receiving nipocalimab plus standard of care compared to placebo plus SOC. Nipocalimab is the first FcRn blocker to demonstrate sustained disease control over six months, with consistent safety and tolerability.
Diversity, Equity & Inclusion in Clinical Trials
Clinical trials historically underrepresented women, especially women of color, in cardiovascular research. Dr. Roxana Mehran discusses the Librexia program. For more info on cardiovascular and stroke trials, visit ResearchIncludesMe.com.
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for ...
CHMP recommends daratumumab SC for newly diagnosed multiple myeloma patients eligible for ASCT, supported by PERSEUS study showing 60% reduction in disease progression or death risk with quadruplet therapy.
Regulatory actions for Sept. 23, 2024
Regulatory snapshots: global drug submissions, approvals, clinical trial approvals, and other decisions involving Amplia, Apellis, Biocon, Biotech, Ipsen, Janssen, Johnson & Johnson, Merck, Novo Nordisk, Pfizer, Samsung Bioepis, Sanofi.
Sanofi Secures First-Line Nod for Sarclisa in Multiple Myeloma Treatment
FDA approved Sanofi’s Sarclisa for newly diagnosed multiple myeloma patients ineligible for stem cell transplant, marking a significant advancement. Sarclisa, combined with VRd, reduces disease progression or death risk by 40%, offering a new treatment option. Sanofi aims to establish Sarclisa as a best-in-class therapy, with ongoing studies for broader applications.
United States Urinary Tract Cancer Treatment Market By Type 2024-2031
The United States Urinary Tract Cancer Treatment Market is projected to reach USD xx.x billion by 2031, driven by advancements in medical technology, increasing prevalence of urinary tract cancers, and growing awareness about early detection and treatment options. Bladder and kidney cancers dominate the market, with treatment options including surgery, chemotherapy, radiation therapy, and immunotherapy. Future growth is expected with advancements in precision medicine, targeted therapies, and immunotherapies.
© Copyright 2025. All Rights Reserved by MedPath